Clinical Trials Browser

Phase 1 × Unknown × pembrolizumab × Clear all

NCT05763004 2024-10-08

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Phase 1 Unknown

140 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06270706 2024-06-12

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Unknown

77 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Longitudinal Immune-phenotyping of HCC Following MK-3475

FIH

Phase 1 First-in-human Study of JS014

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Pembrolizumab + CVA21 in Advanced NSCLC

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer